title: [The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer].
authors.affiliation: Klinik für Strahlenheilkunde, Universitätsklinikum Freiburg, Albert-Ludwigs-Universität Freiburg, Robert‑Koch‑Str. 3, 79106, Freiburg, Deutschland. thomas.brunner@uniklinik-freiburg.de.
authors.forename: Thomas
authors.initials: T
authors.lastname: Brunner
authors.affiliation: , Frankfurt/Main, Deutschland.
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Fokas
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000401:mortality*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007390:International Agencies; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000401:mortality* / Q000628:therapy*; D015995:Prevalence; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine